Clinical Trial Update: Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant and adjuvant trial evaluating anti-PD1 therapy alone or in combinations for locoregionally advanced melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma Stage III, Melanoma Stage IV | Phase 2 | Status: RECRUITING